Powder: -20°C for 3 years | In solvent: -80°C for 1 year
YK-3-237 (B-[2-Methoxy-5-[(1E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propen-1-yl]phenyl]boronic acid) reduces acetylation of mtp53 and exhibits anti-proliferative effects toward triple-negative breast cancer (TNBC) cells carrying mtp53.
説明 | YK-3-237 (B-[2-Methoxy-5-[(1E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propen-1-yl]phenyl]boronic acid) reduces acetylation of mtp53 and exhibits anti-proliferative effects toward triple-negative breast cancer (TNBC) cells carrying mtp53. |
In vitro | YK-3-237 activates SIRT1 enzyme activities in vitro and deacetylation of both mtp53 in a SIRT1-dependent manner. |
別名 | B-[2-Methoxy-5-[(1E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propen-1-yl]phenyl]boronic acid |
分子量 | 372.18 |
分子式 | C19H21BO7 |
CAS No. | 1215281-19-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMF: 30 mg/ml(80.60 mM)
Ethanol: 10 mg/ml(26.86 mM)
DMSO: 30 mg/ml(80.60 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
YK-3-237 1215281-19-8 Chromatin/Epigenetic DNA Damage/DNA Repair Sirtuin YK3237 inhibit B-[2-Methoxy-5-[(1E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propen-1-yl]phenyl]boronic acid p53 breast cancer triple-negative mtp53 Mutant TNBC Inhibitor deacetylation YK 3 237 inhibitor